Quinazolines: Combined type 3 and 4 phosphodiesterase inhibitors

Article abstract of DOI:10.1016/S0960-894X(98)00508-3

A series of quinazolines has been prepared and evaluated for its ability to inhibit cyclic AMP phosphodiesterase type 3, type 4A, 4B and 4D. The most potent inhibitors showed IC₅₀ values in the nanomolar range for type 3 and type 4 isoforms and bind with high affinity to the [³H]rolipram binding site. These quinazolines represent a new family of potent mixed PDE 3 / 4 inhibitors and are expected to have a therapeutic potential.